SIU 2017: Differences in Clinical and Pathological Characteristics Between Patients with Small Renal Masses (T1a) and Larger Renal Masses
Lisbon, Portugal (UroToday.com) The primary objective of this study was to assess clinical differences between patients presenting with a small renal mass (SRM) (cT1a) (<4 cm) and larger renal masses (>cT1b) (>4 cm). Additionally, small RCC masses specifically were compared to large RCC masses.
SIU 2017: Renal Masses at Presentation: Clinical and Treatment Patterns Among Continents
Lisbon, Portugal (UroToday.com) Little is known about the differences in patterns of presentation of renal masses among various continents. The objective of this study was to describe differences at presentation and in treatment among continents in a contemporary population with renal masses.
SIU 2017: The Utility of Subsequent Prostate Biopsies for the Active Surveillance of Prostate Cancer when Genomics and MRI Are Negative
Lisbon, Portugal (UroToday.com) In this panel discussion, led by Dr. Cooperberg, the focus of the talk was on the utility of subsequent prostate biopsies for active surveillance (AS) patients when genomics and mpMRI are negative.
As an introduction, Dr. Cooperberg noted that AS has finally been recognized as the standard of care for low-risk PCa, as opposed to an option. However, those same guidelines do NOT mention high-risk groups, such as African-Americans, younger men, and high volume disease. While AS currenty entails an initial biopsy and a confirmatory biopsy at 6-12 months, following by surveillance regimens that vary significantly, most surveillance protocols still call for repeat biopsies during follow-up. However, along this management course, there are numerous new genomic tests that can be utilized to alter risk level as well as mpMRI. How do these tests affect decision making and can they replace biopsy?
SIU 2017: TP53 p. R337H Germline Mutation Analysis in Patients with Clear Cell Renal Cell Carcinoma
Lisbon, Portugal (UroToday.com) Most cases of Renal Cell Carcinoma (RCC) are classified as sporadic. Clear Cell is the most frequent subtype (80-90%). Several hereditary syndromes are correlated with a higher risk of developing RCC. These are responsible for 3%-5% of RCC cases but this number is most probably under-estimated. In general, 10 syndromes and 12 genes related to RCC have been described up to date.
The Optimal Treatment of Muscle Invasive Urothelial Bladder Cancer with Neoadjuvant Chemotherapy with Cystectomy
Lisbon, Portugal (UroToday.com) Dr. Brausi moderated this SIU-SUO/ESOU debate between Dr. Black and Dr. Khochikar on the topic of neoadjuvant chemotherapy (NAC) in an elderly patient with muscle invasive bladder cancer (MIBC). This was an excellent debate with important points by both debaters – there may not be a right answer, but it was educational nonetheless. Below are the highlights and main points of the discussion.
SIU 2017: COL23A1. Plays an Oncogenic Role in the Clear-Cell Renal Cell Carcinoma
Lisbon, Portugal (UroToday.com) Clear cell renal cell carcinoma (ccRCC) is the most common adult renal neoplasm and its incidence continues to rise steadily. Collagen shift is a fundamental element contributing to the development and progression of ccRCC. The authors aimed to examine the expression of the collagen COL23A1 in ccRCC and its relationship to survival outcomes.
SIU 2017: Controversies in Urology--Bladder Cancer: Old is Gold!
Lisbon, Portugal (UroToday.com) Dr. Risk presented his support for the old traditional white light cystoscopy. Dr. Risk began with stating that there is a need for randomized controlled trials (RCT) to demonstrate a true advantage and improvement in outcomes with the usage of fluorescent cystoscopy (FC), compared to white cystoscopy. So far, the level of evidence for this has been low, with heterogeneity and inconsistency very common. There has also been proof for performance bias, detection bias, and publication bias.